Stanberry L R
Department of Pediatrics, University of Cincinnati College of Medicine, Ohio 45229, USA.
Sex Transm Infect. 1998 Dec;74(6):391-4. doi: 10.1136/sti.74.6.391.
To summarise the current status of genital herpes simplex virus (HSV) vaccine development and provide a discussion of the potential benefits and limitations of genital herpes vaccines.
Literature review.
Genital herpes simplex virus infection has a complex pathogenesis that has contributed to it becoming a serious worldwide problem. In an attempt to control the problem five different types of genital herpes vaccines have been developed. These include inactivated virion derived vaccines, adjuvanted subunit vaccines, vectored vaccines, replication limited live viral vaccines, genetically attenuated live viral vaccines, and nucleic acid vaccines. While available commercially in some parts of the world, inactivated virion derived vaccines have not been proved effective. Of the others, adjuvanted subunit vaccines, replication limited live viral vaccines, and nucleic acid vaccines are currently in clinical trials and vectored vaccines and genetically attenuated live viral vaccines are in preclinical development.
With regard to HSV vaccines in general, it is reasonable to expect that the newer vaccines may protect the individual from developing symptomatic genital herpes but may not protect against asymptomatic viral infection. With widespread use HSV vaccines might help to prevent the spread of genital herpes.
总结单纯疱疹病毒（HSV）生殖器疫苗的研发现状，并讨论生殖器疱疹疫苗的潜在益处和局限性。
文献综述。
单纯疱疹病毒生殖器感染的发病机制复杂，已成为一个严重的全球性问题。为控制该问题，已研发出五种不同类型的生殖器疱疹疫苗。这些包括灭活病毒粒子衍生疫苗、佐剂亚单位疫苗、载体疫苗、复制受限活病毒疫苗、基因减毒活病毒疫苗和核酸疫苗。虽然在世界某些地区有商业化产品，但灭活病毒粒子衍生疫苗尚未被证明有效。其他疫苗中，佐剂亚单位疫苗、复制受限活病毒疫苗和核酸疫苗目前正在进行临床试验，载体疫苗和基因减毒活病毒疫苗正处于临床前开发阶段。
总体而言，对于HSV疫苗，可以合理预期新型疫苗可能保护个体免受有症状的生殖器疱疹感染，但可能无法预防无症状病毒感染。随着广泛使用，HSV疫苗可能有助于预防生殖器疱疹的传播。
